Delving into the Latest Updates on DM-0201 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication

Neuralgia, Postherpetic

Inactive Indication-

Originator Organization

Demotech, Inc.Startup

Active Organization

Demotech, Inc.Startup

Yabao Pharmaceutical Co. Ltd. Beijing

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

单次给药：主要目的：比较中国健康受试者单次使用DM0201贴与Lidoderm®的药代动力学特征；次要目的：比较DM0201贴与Lidoderm®在中国健康受试者中单次给药的安全性、耐受性与粘附性。多次给药：主要目的：比较中国健康受试者多次使用DM0201贴与Lidoderm®的药代动力学特征；次要目的：比较DM0201贴与Lidoderm®在中国健康受试者中多次给药的安全性、耐受性与粘附性。

[Translation]

Single administration: Primary purpose: To compare the pharmacokinetic characteristics of DM0201 patch and Lidoderm® in Chinese healthy subjects after single administration; Secondary purpose: To compare the safety, tolerability and adhesion of DM0201 patch and Lidoderm® in Chinese healthy subjects after single administration. Multiple administration: Primary purpose: To compare the pharmacokinetic characteristics of DM0201 patch and Lidoderm® in Chinese healthy subjects after multiple administration; Secondary purpose: To compare the safety, tolerability and adhesion of DM0201 patch and Lidoderm® in Chinese healthy subjects after multiple administration.

Start Date26 Oct 2024

Sponsor / Collaborator

Yabao Pharmaceutical Co. Ltd. Beijing

[+1]

100 Clinical Results associated with DM-0201

Login to view more data

100 Translational Medicine associated with DM-0201

Login to view more data

100 Patents (Medical) associated with DM-0201

Login to view more data

100 Deals associated with DM-0201

Login to view more data